Primary Immunodeficiencies — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Feasibility of thermal dose painting during magnetic nanoparticle thermal therapy: a computational analysis.
Pawar Shreeniket et al. — International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41813594/
- 2.
Dual storage mechanism via hydrogen bonding and redox in 1D MOF-pillared vanadium oxide for high-performance aqueous ammonium-ion batteries.
Wang Juntao et al. — Journal of colloid and interface science (15 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41707500/
- 3.
Ocular manifestations of
Hwang Jodi et al. — American journal of ophthalmology case reports (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41778090/
- 4.
High-thermal-conductivity integrated EWOD chip for ultra-fast, low-cost pathogen detection.
Zhang Fangzhou et al. — Analytica chimica acta (8 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41813353/
- 5.
Factors predicting STI-positive cervicitis and pelvic inflammatory disease, and implications on antibiotic use: a cross-sectional analysis.
Chawla Shreya et al. — Sexual health (9 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41866150/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Recruiting — Phase 2 — Charite University, Berlin, Germany
https://clinicaltrials.gov/study/NCT03590171
- 2.
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension
Recruiting — Phase 2 — Monash University
https://clinicaltrials.gov/study/NCT05678621
- 3.
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Recruiting — Phase 3 — Takeda
https://clinicaltrials.gov/study/NCT06980480
- 4.
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Recruiting — Phase 3 — Pharvaris Netherlands B.V.
https://clinicaltrials.gov/study/NCT06679881
- 5.
Phase I/II Clinical Trial Stem Cell Gene Therapy in RAG1-Deficient SCID
Recruiting — Na — Leiden University Medical Center
https://clinicaltrials.gov/study/NCT04797260
- 6.
X-linked Moesin Associated Immunodeficiency
Recruiting — Institut National de la Santé Et de la Recherche Médicale, France
https://clinicaltrials.gov/study/NCT06278337
- 7.
A Study of Navenibart in Participants With Hereditary Angioedema
Recruiting — Phase 3 — Astria Therapeutics, Inc.
https://clinicaltrials.gov/study/NCT06842823
- 8.
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)
Recruiting — Phase 2 — Monash University
https://clinicaltrials.gov/study/NCT07202052
- 9.
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting — Sanford Health
https://clinicaltrials.gov/study/NCT01793168
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Primary Immunodeficiencies
Primary immunodeficiencies are a diverse group of over 450 genetic conditions that impair the immune system. Common variable immunodeficiency (CVID) is the most prevalent in adults. Many are significantly underdiagnosed. Immunoglobulin replacement therapy is the mainstay of treatment for antibody deficiencies.
Most Recent Research
BACKGROUND: Spatially confined magnetic nanoparticle thermal therapy (SC-MNTT) can improve the tumor coverage index (CI) when the magnetic field-free region (FFR) is manually steered. However, static steering demands significant time and expertise from experienced control engineers during treatment planning. OBJECTIVE: This study presents a computational framework for automated, dynamic FFR steering combined with real-time tumor boundary temperature control to enhance magnetic nanoparticle thermal therapy (MNTT) for cancer therapy. The framework also supports controlled MNTT treatment planning. METHOD: We integrated the Pennes bioheat transfer equation with a proportional-integral-derivative (PID) controller to maintain the maximum tumor boundary temperature at 46 °C. The magnetic nanoparticle (MNP) heat source was divided into four subdomains to simulate SC-MNTT. A fuzzy logic controller automatically selected the FFR based on four-point temperature measurements and corresponding thermal dose, aiming to maximize CI. We examined the influence of key treatment parameters: maximum treatment temperature (60 or 80 °C), MNP distribution (uniform or Gaussian), sensor noise, and MNP position relative to the tumor center. RESULTS: Automated dynamic FFR steering increased CI by ∼25-35%, depending on these parameters. The highest CI occurred at a maximum treatment temperature of 80 °C with a uniform MNP distribution. Sensor noise had minimal effect, while minimal offset between the MNP position and tumor center was essential for maximizing CI. CONCLUSION: The proposed fuzzy logic-based dynamic FFR steering may reduce reliance on expert control engineers for SC-MNTT treatment planning. Future work will focus on pre-clinical implementation and experimental validation of the control system.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.